A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system      

Posted on Friday, March 23, 2012 - 12:51, By: Amy Madsen
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.

The MDA-supported ALS Therapy Development Institute will collaborate with Biogen Idec and UCB to test CDP7657, a compound that modulates the immune system

Posted on Wednesday, December 21, 2011 - 17:04, By: Margaret Wahl
The ALS Therapy Development Institute (ALS TDI), an MDA-supported, nonprofit biotechnology organization dedicated to developing effective treatments for amyotrophic lateral sclerosis (ALS), will collaborate with two major biotechnology companies to investigate a potential treatment that modulates...

Research about FUS-TDP43 interaction, a newly identified SOD1 mutation, and historical controls in trials; and webinars about the TDP43 mouse and the ceftriaxone trial

Posted on Friday, September 9, 2011 - 14:27, By: Amy Madsen
FUS and TDP43 work together in fruit flies In a fruit fly research model of inherited ALS, human FUS and TDP43 proteins work together on some processes necessary for the long-term survival of muscle-controlling nerve cells (motor neurons), reports a research team at Columbia University Medical...

'ALS Starter Kit' will address equipment evaluations, health care teams, Medicare and other topics for those with a recent diagnosis and their families

Posted on Friday, May 20, 2011 - 14:41, By: Miriam Davidson
Every day in the United States, about 13 people receive a diagnosis of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease). That’s 5,000 Americans a year who are new to this disease. MDA's ALS Division wants to reach out to these people and their families, encourage and support them, and...

ALS TDI scientists provided updates on the development and testing of several therapies designed to slow and stop ALS     

Posted on Thursday, April 21, 2011 - 10:45, By: Amy Madsen
The state of the science in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease), current lines of research, efforts to establish a TDP43 research mouse colony, and a primer on protein-based therapies were the topics of a webcast on April 7, 2011, presented by ALS Therapy Development...